Efficacy and safety of olverembatinib in adult BCR :: ABL1 ‐positive ALL with T315I mutation or relapsed/refractory disease
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19804 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Weiyang Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mutation, Protein Kinase Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Third‐generation tyrosine kinase inhibitors (TKIs) have much potential for the treatment of BCR::ABL1 ‐positive leukaemia, particularly that harbouring the ABL1 T315I mutation. Olverembatinib (HQP1351), a novel third‐generation TKI, has favourable efficacy and safety profiles in chronic myeloid leukaemia. Here, we present the clinical findings from 31 BCR::ABL1 ‐positive acute lymphoblastic leukaemia (ALL) patients who received olverembatinib. Among the 14 patients with overt relapsed/refractory (R/R) disease (including 10 with the T315I mutation), 71.4% achieved an overall response. Of the other 17 patients with minimal residual disease (MRD)‐positive ALL (including 14 with the T315I mutation), 60.0% and 47.1% achieved MRD flow negativity and complete molecular remission, respectively. With a median follow‐up time of 16.3 months, the median event‐free survival and overall survival were 3.9 and 8.3 months respectively, in overt R/R patients, and 11.5 and 18.4 months in MRD‐positive patients. Allogeneic haematopoietic stem cell transplantation further improved outcomes among responders. The safety profile was generally manageable. This study suggests that olverembatinib‐based therapy is another promising option for BCR::ABL1 ‐positive ALL in addition to ponatinib, especially for patients with MRD‐positive disease and a single T315I mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, C…
- Department of Hematology, Bei Zhan Hospital, Shanghai, China.
ORCID-Profile: Weiyang Liu, Jian-Qing Mi
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Liu, W., Wang, C., Ouyang, W., Hao, J., Ren, J., Peng, L., Tang, S., Liu, Y., Zhu, Y., Weng, X., Jing, D., Chen, S., Wang, J., & Mi, J. Q. (2024). Efficacy and safety of olverembatinib in adult BCR :: ABL1 ‐positive ALL with T315I mutation or relapsed/refractory disease. British Journal of Haematology. https://doi.org/10.1111/bjh.19804
Vancouver
Liu W, Wang C, Ouyang W, Hao J, Ren J, Peng L, et al. Efficacy and safety of olverembatinib in adult BCR :: ABL1 ‐positive ALL with T315I mutation or relapsed/refractory disease. British Journal of Haematology. 2024. doi:10.1111/bjh.19804
BibTeX
@article{Liu2024,
author = {Liu, Weiyang and Wang, Cheng and Ouyang, Wanyan and Hao, Jie and Ren, Jiayi and Peng, Lijun and Tang, Sijie and Liu, Yuanfang and Zhu, Yongmei and Weng, Xiangqin and Jing, Duohui and Chen, Saijuan and Wang, Jin and Mi, Jian-Qing},
title = {Efficacy and safety of olverembatinib in adult BCR :: ABL1 ‐positive ALL with T315I mutation or relapsed/refractory disease},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19804}
}
EUVIMED